WO2004061103A1 - 新規タンパク質及びそれをコードする遺伝子 - Google Patents
新規タンパク質及びそれをコードする遺伝子 Download PDFInfo
- Publication number
- WO2004061103A1 WO2004061103A1 PCT/JP2003/017064 JP0317064W WO2004061103A1 WO 2004061103 A1 WO2004061103 A1 WO 2004061103A1 JP 0317064 W JP0317064 W JP 0317064W WO 2004061103 A1 WO2004061103 A1 WO 2004061103A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- gene
- expression
- amino acid
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 406
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 214
- 230000014509 gene expression Effects 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 100
- 201000010099 disease Diseases 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 150000001413 amino acids Chemical class 0.000 claims abstract description 49
- 238000012216 screening Methods 0.000 claims abstract description 42
- 230000002159 abnormal effect Effects 0.000 claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 30
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 16
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 75
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 72
- 201000005202 lung cancer Diseases 0.000 claims description 72
- 239000012634 fragment Substances 0.000 claims description 56
- 108020004414 DNA Proteins 0.000 claims description 55
- 241001465754 Metazoa Species 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 36
- 239000000126 substance Substances 0.000 claims description 34
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 abstract description 9
- 230000003449 preventive effect Effects 0.000 abstract description 8
- 238000007792 addition Methods 0.000 abstract description 5
- 238000012217 deletion Methods 0.000 abstract description 5
- 230000037430 deletion Effects 0.000 abstract description 5
- 230000002018 overexpression Effects 0.000 abstract 5
- 235000018102 proteins Nutrition 0.000 description 176
- 210000004027 cell Anatomy 0.000 description 128
- 239000002585 base Substances 0.000 description 118
- 210000001519 tissue Anatomy 0.000 description 99
- 238000003752 polymerase chain reaction Methods 0.000 description 47
- 239000002299 complementary DNA Substances 0.000 description 42
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 41
- 201000005249 lung adenocarcinoma Diseases 0.000 description 41
- 241000282414 Homo sapiens Species 0.000 description 37
- 239000002773 nucleotide Substances 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 36
- 239000000523 sample Substances 0.000 description 24
- 239000002609 medium Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000010195 expression analysis Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000004102 animal cell Anatomy 0.000 description 9
- 206010017758 gastric cancer Diseases 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000238631 Hexapoda Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000000628 antibody-producing cell Anatomy 0.000 description 7
- 101150100617 ced-8 gene Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000618525 Homo sapiens Membrane transport protein XK Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 102000055154 human XK Human genes 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100448444 Caenorhabditis elegans gsp-3 gene Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241001137251 Corvidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 3
- 101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 3
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 101100393821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GSP2 gene Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 235000016127 added sugars Nutrition 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- -1 organic acid ammonium salts Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 206010023774 Large cell lung cancer Diseases 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000578940 Homo sapiens PDZ domain-containing protein MAGIX Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 208000021964 McLeod neuroacanthocytosis syndrome Diseases 0.000 description 1
- 208000026486 McLeod syndrome Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100028326 PDZ domain-containing protein MAGIX Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000007040 lung development Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Definitions
- the present invention relates to a protein specifically upregulated in abnormal cells or tissues (particularly lung cancer cells or lung cancer tissues), a gene encoding the protein, a recombinant vector containing the gene, and a transformation containing the recombinant vector.
- the present invention relates to a screening method and a screening kit for a substance for preventing and treating a disease (particularly lung cancer) associated with enhanced expression of the above-mentioned gene, using as an index.
- Conventional technology Conventional technology
- Lung cancer is on the rise worldwide, with the number of new cases in Japan expected to reach 110,000 for men and 37,000 for women by 2015. According to the book, the annual death toll from lung cancer in 1999 was about 52,000, and from 1993 lung cancer became the number one cancer mortality rate among men, and gastric cancer among women. It is second only to Japan.
- the 5-year survival rate which is the rate of survival for 5 years from the start of treatment for lung cancer, is said to be 25 to 30%, and there is a social need for effective treatments for lung cancer.
- the present invention firstly provides a protein specifically upregulated in abnormal cells or tissues (particularly lung cancer cells or lung cancer tissues), a gene encoding the protein, a recombinant vector containing the gene,
- An object of the present invention is to provide a transformant containing a recombinant vector, and an antibody against the protein or a fragment thereof.
- the present invention relates to a method for enhancing the expression of the above-described genes using the expression level of a gene encoding a protein that is specifically enhanced in abnormal cells or tissues (particularly lung cancer cells or lung cancer tissues) as an index.
- An object of the present invention is to provide a diagnostic method and a diagnostic kit for a disease involved (particularly lung cancer).
- the present invention provides, thirdly, the expression enhancement of the above-described genes, using the effect of reducing the expression level of a gene encoding a protein which is specifically enhanced in abnormal cells or tissues (particularly lung cancer cells or lung cancer tissues) as an index.
- An object of the present invention is to provide a screening method and a screening kit for a substance which prevents or treats a disease (especially lung cancer) associated with the disease.
- the present invention provides the following protein, gene, recombinant vector, transformant, anti- ⁇ : or fragment thereof, diagnostic method and diagnostic kit, and screening method and screen Provide kits for testing. ,
- a protein consisting of the amino acid sequence of SEQ ID NO: 2
- b a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of SEQ ID NO: 2, and whose expression is specifically enhanced in abnormal cells or tissues
- kits for diagnosing a disease associated with enhanced expression of the gene encoding the protein comprising an oligonucleotide or polynucleotide capable of hybridizing to the nucleic acid encoding the protein according to (1).
- a diagnostic kit for a disease associated with enhanced expression of a gene encoding the protein comprising an antibody or a fragment thereof capable of reacting with the protein according to (1).
- a candidate substance for a disease associated with enhanced expression of the gene using the effect of reducing the expression level of the gene in a cell or tissue in which the expression level of the gene encoding the protein according to (1) is increased as an index
- a screen for a substance for preventing or treating a disease associated with enhanced expression of the gene encoding the protein comprising an oligonucleotide or polynucleotide capable of hybridizing to the nucleic acid encoding the protein according to (1).
- a kit for rearing comprising an oligonucleotide or polynucleotide capable of hybridizing to the nucleic acid encoding the protein according to (1).
- kits for screening of a substance for preventing or treating a disease associated with enhanced expression of a gene encoding the protein comprising an antibody or a fragment thereof capable of reacting with the protein according to (1).
- FIG. 1 is a graph showing the expression levels of mRNA that reacts with the 230349_at_ul33B probe in human lung adenocarcinoma tissue and normal human lung tissue.
- FIG. 2 is a graph showing the expression level of raRNA reacting with the 230349-at-U133B probe in normal human tissues.
- FIG. 3 is a diagram showing the results of electrophoresis of a DNA fragment obtained by the RACE method (Rapid amplification cDNA ends).
- FIG. 4 is a view showing an alignment result between the nucleotide sequence of gene # 15 and the nucleotide sequence of LOC139320.
- FIG. 5 is a diagram (continuation of FIG. 4) showing the alignment result between the nucleotide sequence of gene # 15 and the nucleotide sequence of L0C139320.
- FIG. 6 shows the presence or absence of expression of gene # 15 and L0C139320 in lung adenocarcinoma tissue.
- FIG. 7 is a diagram showing the presence or absence of expression of gene # 15 in lung adenocarcinoma tissues (12 cases) and normal lung tissues (4 cases).
- FIG. 8 is a diagram showing the presence or absence of the expression of gene # 15 in cancer cells isolated from lung adenocarcinoma tissue by microdissection.
- FIG. 9 is a diagram showing the presence or absence of the expression of gene # 15 in activated or inactive mononuclear cells or lymphocytes and normal human tissues.
- FIG. 10 is a diagram showing the presence or absence of expression of gene # 15 in human gastric cancer, hepatocellular carcinoma, and colon cancer.
- FIG. 11 is a view showing an alignment result between the amino acid sequence of the protein encoded by the gene # 15 and the amino acid sequence of the human XK protein.
- FIG. 12 is a view showing an alignment result between the amino acid sequence of the protein encoded by gene # 15 and the amino acid sequence of the C. elegans Ced8 protein. BEST MODE FOR CARRYING OUT THE INVENTION
- the protein of the present invention is a protein shown in the following (a) or (b).
- protein (a) a protein consisting of the amino acid sequence of SEQ ID NO: 2 (hereinafter referred to as “protein (a)”)
- Protein (b) a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of SEQ ID NO: 2 and which is specifically upregulated in abnormal cells or tissues (hereinafter referred to as “ Protein (b)
- the protein (a) or (b) is a protein that is specifically upregulated in abnormal cells or tissues (including abnormal organs).
- specifically upregulated in abnormal cells or tissues means that expression is not upregulated in normal cells or tissues but is increased only in abnormal cells or tissues.
- abnormal cell or tissue refers to a cell or tissue that exhibits some abnormal state in association with any disease, and its type is a protein.
- Examples include lung cancer cells and lung cancer tissues.
- lung cancer include lung adenocarcinoma, lung squamous cell carcinoma and large cell Examples include lung cancer and small cell lung cancer.
- Increased expression of protein (a) or (b) is not observed in cells or tissues derived from cancers such as gastric cancer, hepatocellular carcinoma, and colorectal cancer.
- protein (a) or (b) is considered to be upregulated especially in lung cancer among cancers.
- protein (a) or (b) is considered to be upregulated in lung adenocarcinoma cells or lung adenocarcinoma tissues, especially among lung cancers.
- protein ( a ) is 44.7% each of human XK protein (Kell brood group precursor gene) and nematode CED8 protein. And 19.4 ° / 0 homology (see FIGS. 11 and 12). Both human XK protein and C. elegans CED8 protein are expected to be expressed on cell membranes and function as transporters. Human XK protein is more likely to transport the Kell antigen protein precursor or a part of it in erythrocytes, and mutation of human XK protein causes dysfunction of XK protein, causing Kell antigen to disappear from the erythrocyte surface. Is thought to induce erythrocyte morphology abnormalities and eventually cause squamous erythrocytosis (Ho.
- CED8 function in the early stages of nematode lung development delays the timing of programmed cell death, and is considered to be one of the regulators of apoptosis.
- the function of the CED8 protein at or downstream thereof is involved in cell death (Stanfiel d. GM et al., Molecular Cell, Vol. 5, 423-433, 2000).
- the protein of the present invention is expected to act as a transporter having a plurality of transmembrane regions,
- transporting substances required for the development of lung adenocarcinoma or transporting substances essential for the growth and survival of cancer cells it may be involved in the development and progression of lung adenocarcinoma. It may be related to apoptosis control in the same way as described above.
- the number of amino acids to be deleted, substituted or added in the amino acid sequence of SEQ ID NO: 2 depends on abnormal cells or abnormal tissues (particularly lung cancer cells or lung cancer tissues). Is not particularly limited as long as the expression is specifically enhanced in
- the number is one or more, preferably one or several, and the specific range is usually 1 to 100, preferably 1 to 50, and more preferably 1 to 10.
- the amino acid sequence of the protein (b) has a homology of usually 15% or more, preferably 40% or more, and more preferably 70 ° / 0 or more with the amino acid sequence of the protein (a).
- the position of the amino acid to be deleted, substituted or added in the amino acid sequence of SEQ ID NO: 2 is not particularly limited as long as the expression is specifically enhanced in abnormal cells or tissues (particularly lung cancer cells or lung cancer tissues). Absent.
- the ninth amino acid Glu is the amino acid Gly
- the tenth amino acid Arg is the amino acid Gly
- the thirteenth amino acid Thr is the amino acid Ala
- the twenty-fifth amino acid Asn is amino acid Asp
- 26th amino acid Val is amino acid Ala
- 29th amino acid Val is amino acid Asp
- 76th amino acid Glu is amino acid Gly
- 83rd amino acid Thr is amino acid Ala
- the 90th amino acid Ser is the amino acid Pro
- the 11th amino acid Leu is the amino acid Pro
- the 112th amino acid Ser is the amino acid Pro
- the 116th amino acid His is the amino acid Arg
- 1 2 8 Amino acid Glu is amino acid Lys, 1 4 5 amino acid Pro is amino acid
- the protein (b) may be a protein in which a mutation such as deletion, substitution, or addition has been introduced into the protein (a), or a mutation in which a deletion, substitution, addition, or the like has been introduced. Also included are naturally occurring proteins and proteins into which mutations such as deletions, substitutions, and additions have been artificially introduced. Examples of naturally occurring proteins in which mutations such as deletions, substitutions, and additions have been introduced include, for example, mammals including humans (eg, humans, monkeys, pests, sheep, goats, And proteins derived from horses, pigs, rabbits, dogs, cats, mice, rats, etc. (including proteins that can be produced by polyps in these mammals).
- mammals including humans (eg, humans, monkeys, pests, sheep, goats, And proteins derived from horses, pigs, rabbits, dogs, cats, mice, rats, etc. (including proteins that can be produced by polyps in these mammals).
- the proteins ( a ) and (b) include both proteins with added sugar chains and proteins without added sugar chains.
- the type, position, etc. of the sugar chains added to the protein vary depending on the type of host cell used in the production of the protein.S For proteins with added sugar chains, any host cell can be used.
- the resulting protein is also included.
- the proteins (a) and (b) also include pharmaceutically acceptable salts thereof.
- the gene encoding the protein (a) or (b) can be obtained, for example, by preparing a cDNA library using mRNA extracted from human lung cancer cells or lung cancer tissues including humans, It can be obtained by screening a clone containing the target DNA from a cDNA library using a probe synthesized based on the sequence.
- the steps of preparing a cDNA library and screening a clone containing the desired DNA will be described. [Preparation of cDNA library]
- RNA is obtained by the affinity column method, batch method, and the like.
- poly (A +) RNA (mRNA) may be fractionated by sucrose density gradient centrifugation or the like.
- a single-stranded cDNA is synthesized using an oligo dT primer and a reverse transcriptase, and then a double-stranded cDNA is synthesized from the single-stranded cDNA.
- the thus obtained double-stranded cDNA is inserted into an appropriate cloning vector to prepare a recombinant vector, and a host cell such as Escherichia coli is transformed with the recombinant vector to obtain a tetracycline resistant, By selecting transformants using ampicillin resistance as an index, cDNA libraries can be obtained.
- the closing vector for preparing a cDNA library may be any vector capable of autonomous replication in a host cell, and for example, a phage vector, a plasmid vector, and the like can be used.
- a host cell for example, Escherichia coli or the like can be used.
- Transformation of a host cell such as Escherichia coli can be performed by a method of adding a recombinant vector to a competent cell prepared in the presence of calcium chloride, magnesium chloride, or rubidium chloride.
- plasmid When plasmid is used as a vector, it is preferable to contain a drug resistance gene such as tetracycline or ampicillin.
- a commercially available kit for example, SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (manufactured by Gibco BRL), ZAP-cDNA Synthesis Kit (manufactured by Stratagene), or the like can be used. [Screening of clones containing the desired DNA]
- primers are synthesized based on the nucleotide sequence of SEQ ID NO: 1 and used to perform polymerase chain reaction (PCR). Obtain a PCR amplified fragment.
- the PCR amplified fragment may be subcloned using an appropriate plasmid vector.
- the primer set used for the PCR is not particularly limited, and can be designed based on the nucleotide sequence shown in SEQ ID NO: 1.
- the target DNA can be obtained by performing co-prime-hybridization or plaque hybridization on the cDNA library using the PCR amplified fragment as a probe.
- a PCR-amplified fragment labeled with an isotope for example, 32 P, 35 S
- biotin for example, digoxygen, alkaline phosphatase, or the like
- a clone containing the desired DNA can also be obtained by expression screening such as immunoscreening using an antibody.
- the nucleotide sequence of the obtained DNA is obtained by digesting the DNA fragment as it is or after digesting with an appropriate restriction enzyme or the like, and incorporating the DNA fragment into a vector by a conventional method. Can be determined using the dideoxynucleotide chain termination method.
- a nucleotide sequence analyzer such as 3773 DNA Sequencer (manufactured by Perkin Elmer) is usually used.
- the gene encoding the protein (a) or (b) contains an open reading frame encoding the protein (a) or (b) and a stop codon located at the 3, terminal thereof. Further, the gene encoding the protein (a) or (b) can include an untranslated region (UTR) at the 5 ′ end and the Z or 3 ′ end of the open reading frame. Examples of the gene encoding the protein (a) include a gene containing a DNA consisting of the 103rd to 148th nucleotide sequence in the nucleotide sequence of SEQ ID NO: 1.
- the 103rd to 148th base sequence of the base sequence described in SEQ ID NO: 1 is an open reading frame encoding the protein (a), and
- the translation start codon is located at the 103rd to 105th base sequence, and the termination codon is located at the 148th to 149th base sequence.
- the nucleotide sequence of the gene encoding the protein (a) is not particularly limited as long as it encodes the protein (a).
- the nucleotide sequence of the open reading frame is one of the nucleotide sequences described in SEQ ID NO: 1. 03-1148 Not limited to the eighth base sequence.
- the gene encoding the protein (a) can also be obtained by chemical synthesis according to its nucleotide sequence.
- Chemical synthesis of DNA is performed using commercially available DNA synthesizers, such as a DNA synthesizer using the thiophosphite method (manufactured by Shimadzu Corporation) and a DNA synthesizer using the phosphoramidite method (Perkin Pharma Co., Ltd.) ).
- Examples of the gene encoding the protein (b) include, for example, DNA that is complementary to the DNA consisting of the 103rd to 148th nucleotides in the nucleotide sequence of SEQ ID NO: 1 under stringent conditions. And a gene containing DNA encoding a protein that specifically hybridizes with abnormal cells or tissues (especially lung cancer cells or lung cancer tissues).
- the “stringent conditions” include, for example, the conditions of 42 ° C., 2 ⁇ SSC and 0.1% SDS, preferably the conditions of 65 ° C, 0.1 ⁇ SSC and 0.1% SDS.
- the DNA to be soybean should be at least 50 ° / 0 or more, preferably 70% or more, with DNA consisting of the 103rd to 148th base sequence of the base sequence described in SEQ ID NO: 1.
- a DNA having a homology of 90% or more is used.
- the base a of the 126th base is the base g
- the base a of the 128th base is the base g
- the ninth base a is the base g
- the 370th base is the base c
- the 414th base t is the base c
- the 434th base t is the base c
- the 434th base Base t of base c as base c base 449 of base 449 as base g
- base g of base 484 as base a
- base of base 65 3 t is base c
- 701st base a is base g
- 782nd base a is base g
- 824th base a is base g, 8 7 7th base t to base c, 948th base t to base c, 989th base a to base g, 10 25th base t to base c, 1 0 9 4th base t to base c 1 16 3rd
- the gene encoding the protein (b) is, for example, a protein (a) Can be obtained by artificially introducing a mutation into a gene coding for using a known method such as site-directed mutagenesis. Mutations are introduced using, for example, a mutation introduction kit, for example, Mutant-K (manufactured by TAKARA), Mutant-G (manufactured by TAKAR A), or LA PCR in vitro Mutagenesis series kit of TAKARA. be able to.
- a gene whose base sequence has already been determined can be obtained by chemical synthesis according to the base sequence.
- the proteins ( a ) and (b) can be produced, for example, by expressing genes encoding the respective proteins in host cells according to the following steps.
- DNA fragment of an appropriate length containing the coding region of the target protein is prepared.
- DNA is prepared by substituting bases so that the base sequence of the coding region of the target protein becomes an optimal codon for expression in a host cell.
- a recombinant vector is prepared by inserting this DNA fragment into the downstream of a promoter of an appropriate expression vector, and the recombinant vector is introduced into an appropriate host cell to produce a trait capable of producing a desired protein.
- An invert is obtained.
- the above-mentioned DNA fragment must be incorporated into a vector so that its function can be exhibited.
- the vector may be a cis element such as an enhancer, a splicing signal, a poly-A-added signal, or a selection marker. (Eg, dihydrofolate reductase gene, ampicillin resistance gene, neomycin resistance gene), liposome binding sequence (SD sequence) and the like.
- the expression vector is not particularly limited as long as it is capable of autonomous replication in a host cell, and includes, for example, a plasmid vector, a phage vector, A virus vector or the like can be used.
- Plasmid vectors include, for example, Escherichia coli-derived plasmids (for example, pRSET, pBR322, pBR325, pUCll
- phage vectors for example, e phage (e.g., Char on4A, Charon21A, EMBL3, EMBL4, ⁇ gtlO s ⁇ gtll s ⁇ ZAP) mentioned force S, are, as the viral vector, e.g., retroviral, animal viruses such as vaccinia Angeles, Vacu port virus, etc. Insect viruses.
- any of prokaryotic cells, yeast, animal cells, insect cells, plant cells, etc. may be used as long as the target gene can be expressed.
- animal individuals, plant individuals, silkworms, etc. may be used.
- a bacterium When a bacterium is used as a host cell, for example, ⁇ Escherichia genus such as Escherichia coli, Bacillus genus such as Bacillus subtilis, Pseudomonas genus such as Pseudomonas put ida, etc. And bacteria belonging to the genus Rhizobium, such as Rhizobiutn mel iloti, can be used as host cells. Specifically, Escherichia coli XLl_Blue, Escherichia coli XL2-Blue, Escherichia coli DH1, Escherichia coli K12, Escherichia coli JM10
- Escherichia coli such as Escherichia coli HB101 and Bacillus subtilis such as Bacillus subtilis MI114 and Bacillus subtilis 207-21 can be used as host cells.
- Promoter In this case is not particularly limited as long as it can be expressed in bacteria such as Escherichia coli, derived from for example, trp promoter, lac promoter, P L promoter, P R promoter of Escherichia coli or phage, such as promoter Can be used. Also, artificially designed and modified promoters such as the tac promoter, lacT7 promoter and let I promoter can be used. Wear.
- the method for introducing the recombinant vector into the bacterium is not particularly limited as long as it can introduce DNA into the bacterium.
- a method using calcium ions, an electoral portation method, and the like can be used.
- Saccharomyces cerevisiae Saccharo myces cerevisiae
- Schizosaccharose hon Schizosaccharorayce s pombe
- Pichia pastoris Pichia pastoris and the like
- the promoter is not particularly limited as long as it can be expressed in yeast.
- ADH promoter, A0X1 promoter and the like can be used.
- the method for introducing the recombinant vector into yeast is not particularly limited, as long as it is a method capable of introducing DNA into yeast.
- an elect-portion method, a spheroplast method, a lithium acetate method and the like can be used.
- monkey cells such as COS-7, Vero, Chinese hamster ovary cells (CH0 cells), mouse L cells, rat GH3, and human FL cells can be used as host cells.
- the promoter in this case is not particularly limited as long as it can be expressed in animal cells.
- examples include SR o; promoter, SV40 promoter, LTR (Long Terminal Repeat) promoter, CMV promoter, and early human megalovirus. Gene promoters and the like can be used.
- the method for introducing the recombinant vector into animal cells is not particularly limited as long as it is a method capable of introducing DNA into animal cells.
- an electroporation method, a calcium phosphate method, a lipofection method and the like can be used.
- ovarian cells of Spodoptera frugiperda When insect cells are used as hosts, ovarian cells of Spodoptera frugiperda, Ovarian cells of Trichoplusia ni, cultured cells derived from silkworm ovary, and the like can be used as host cells.
- Spodoptera frugiperda ovary cells such as Sf9 and Sf21
- Trichoplusia ni ovary cells such as High 5, BTI-TN-5B1-4 (manufactured by Invitrodin), etc., Bombyx mori N4 etc. as cultured cells derived from silkworm ovaries Is mentioned.
- the method for introducing the recombinant vector into insect cells is not particularly limited, as long as DNA can be introduced into insect cells.
- a calcium phosphate method, a ribosorption method, an electroporation method, or the like can be used.
- a transformant into which the recombinant vector incorporating DNA encoding the desired protein has been introduced is cultured according to a conventional culture method.
- the transformant can be cultured according to a conventional method used for culturing host cells.
- a medium for culturing a transformant obtained by using a microorganism such as Escherichia coli or yeast as a host cell contains a carbon source, a nitrogen source, inorganic salts, and the like, which can be used by the microorganism, to efficiently culture the transformant.
- a natural medium or a synthetic medium may be used as long as the medium can be used for the above.
- carbon source carbohydrates such as glucose, fructose, sucrose and starch, organic acids such as acetic acid and propionic acid, and alcohols such as ethanol and propanol can be used.
- Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate and other inorganic or organic acid ammonium salts, peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolyzate can be used.
- potassium phosphate monobasic, potassium phosphate dibasic, magnesium phosphate, magnesium sulfate, sodium chloride, sodium sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like can be used.
- Culture of a transformant obtained by using a microorganism such as Escherichia coli or yeast as a host cell is performed under aerobic conditions such as shaking culture or aeration and stirring culture.
- the culture temperature is usually 25 to 37 ° C, and the culture time is usually 12 to 48 hours.
- ⁇ is maintained at 6 to 8.
- the pH can be adjusted using an inorganic acid, an organic acid, an alkali solution, urea, calcium carbonate, ammonia, or the like.
- an antibacterial substance such as ampicillin or tetracycline may be added to the medium as needed.
- an indicator When culturing a microorganism transformed with an expression vector using an inducible promoter as a promoter, an indicator may be added to the medium as necessary.
- an indicator For example, when culturing a microorganism transformed with an expression vector using the lac promoter, isopropyl-1-j3-D-thiogalactopyranoside is used, and when culturing a microorganism transformed with an expression vector using the trp promoter, indoleacryl is used. An acid or the like may be added to the medium.
- a medium for culturing the transformant obtained using animal cells as host cells commonly used RPMI 1640 medium, Eagle's MEM medium, DMEM medium, Hara F12 medium, Ham F12K medium, or fetal calf A medium containing serum or the like can be used.
- Transformants are usually cultured at 5 ° / ° C. The reaction is performed at 37 ° C for 3 to 103 in the presence of CO 2 .
- antibiotics such as kanamycin, penicillin, streptomycin, etc. may be added to the medium.
- a medium for culturing a transformant obtained by using insect cells as host cells commonly used TW-FH medium (Pharmingen), Sf-900 II SFM medium (Gibco BRL) Culture of a transformant that can use ExCel400, ExCell405 (manufactured by JRH Biosciences) or the like is usually performed at 27 ° C. for 3 to 10 days.
- an antibacterial substance such as gentamicin may be added to the medium as needed.
- the target protein can also be expressed as a secreted protein or a fusion protein.
- proteins to be fused are: 3] galactosidase, protein A, the IgG binding region of protein A, chloramphenicone acetinoletransferase, poly (A rg), poly (G 1 u), Protein &, maltose binding protein, daltathione S-transferase, polyhistidine chain (His-tag), S peptide, DNA binding protein domain, Tac antigen, thioredoxin, green fluorescein protein and the like.
- the target protein By collecting the target protein from the culture of the transformant, the target protein can be obtained.
- the “culture” includes any of culture supernatant, cultured cells, cultured cells, and crushed cells or cells.
- the target protein When the target protein is accumulated in the cells of the transformant, the cells in the culture are collected by centrifuging the culture, and the cells are washed, and then the cells are disrupted. The protein to be extracted is extracted. If the target protein is secreted extracellularly from the transformant, culture supernatant
- the protein (a) or (b) thus obtained can be obtained by solvent extraction, salting out using ammonium sulfate, desalting, organic solvent precipitation, getylaminoethyl (DEAE) -sepharose, ion exchange chromatography, hydrophobic Purification can be carried out by a chromatographic method, a gel filtration method, an affinity chromatography method, or the like.
- the protein (a) or (b) can also be produced based on its amino acid sequence by a chemical synthesis method such as the Ftnoc method (fluorylmethyloxycarbol method) and the tBoc method (t-butyloxycarbonyl method). .
- a chemical synthesis method such as the Ftnoc method (fluorylmethyloxycarbol method) and the tBoc method (t-butyloxycarbonyl method).
- Ftnoc method fluorylmethyloxycarbol method
- tBoc method t-butyloxycarbonyl method
- the antibody or a fragment thereof of the present invention is an antibody or a fragment thereof capable of reacting with the protein (a) or (b).
- antibody includes both monoclonal antibodies and polyclonal antibodies, and “monoclonal antibodies and polyclonal antibodies” include all classes of monoclonal antibodies and polyclonal antibodies.
- the term “antibody” includes antiserum obtained by immunizing an immunized animal such as a heron or a mouse with the protein of (a) or (b), a human antibody, and a humanized form obtained by genetic recombination. Antibodies are also included.
- the “antibody fragment” includes Fab fragments, F (ab) ′ 2 fragments, single-chain antibodies (scFv) and the like.
- the antibody or fragment thereof of the present invention can be prepared by using the protein (a) or (b) as an antigen for immunization.
- the antigen for immunization include (i) a crushed cell or tissue expressing the protein (a) or (b) or a purified product thereof, and (ii) a protein (a) Alternatively, a recombinant protein expressed by introducing the gene encoding (b) into a host such as Escherichia coli, insect cells or animal cells, and (iii) a chemically synthesized peptide can be used.
- mammals such as rats, mice, guinea pigs, rabbits, sheep, sheep, horses, and horses are immunized using immunizing antigens.
- immunized animal a mouse is preferably used because an antibody can be easily produced.
- immunization in order to induce antibody production, it is preferable to carry out immunization a plurality of times after emulsification using an immune auxiliary such as Freund's complete adjuvant.
- an immune auxiliary such as Freund's complete adjuvant.
- an immune auxiliary such as Freund's complete adjuvant.
- the immunizing aid Freund's complete adjuvant (FCA), incomplete Freund's adjuvant (FIA), aluminum hydroxide gel, and the like can be used.
- the dose of the antigen per mammal can be appropriately set according to the type of mammal, but in the case of mice, it is usually 50%. ⁇ 500 ig.
- the administration site is, for example, intravenous, subcutaneous, intraperitoneal or the like.
- the immunization is usually performed at intervals of several days to several weeks, preferably at intervals of four days to three weeks, for a total of 2 to 8, preferably 2 to 5 immunizations. Then, 3 to 10 days after the last immunization day, the antibody titer against the protein (a) or (b) is measured, and after the antibody titer increases, blood is collected to obtain an antiserum.
- the measurement of the antibody titer can be performed by enzyme immunoassay (ELISA), radioimmunoassay (RIA) or the like.
- a mammal is immunized with an immunizing antigen in the same manner as in the case of the polyclonal antibody, and antibody-producing cells are collected 2 to 53 days after the final immunization.
- the antibody-producing cells include spleen cells, lymph node cells, thymocytes, peripheral blood cells, and the like. Spleen cells are generally used.
- myeloma cells to be fused with the antibody-producing cells generally available cell lines derived from mammals such as humans and mice can be used.
- the cell line to be used is preferably a cell line which has drug selectivity, cannot survive in a selection medium (for example, HAT medium) in an unfused state, and can survive only in a state fused to an antibody-producing cell.
- myeloma cells include mouse myeloma cell lines such as P3X63-Ag. 8. Ul (P3U1), P3 / NSI 8-Ag4-1, and Sp2 / 0-Agl4.
- a predetermined ratio of antibody-producing cells to myeloma cells (for example, 1: 1) is used in animal cell culture medium such as serum-free DMEM, RPMI-1640 medium, or the like. 1-1: 10) and perform a fusion reaction in the presence of a cell fusion promoter such as polyethylene glycol or by electric pulse treatment (for example, electroporation).
- a cell fusion promoter such as polyethylene glycol or by electric pulse treatment (for example, electroporation).
- the cells are cultured using a selection medium to select the desired hybridoma.
- screening is performed to determine whether the target antibody is present in the culture supernatant of the grown hybridoma. Screening of Hypri-Doma may be performed according to a usual method, and is not particularly limited. For example, a part of the culture supernatant contained in a well grown as a hybridoma can be collected and screened by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or the like.
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- the cloning of the hybridoma can be performed by, for example, the limiting dilution method, the soft agar method, the fibrin gel method, the fluorescence excitation cell sorter method, etc., and finally obtain the hybridoma that produces the monoclonal antibody.
- an ordinary cell culture method or the like can be used as a method for collecting a monoclonal antibody from the obtained hybridoma.
- the Te cell culture method smell, for example, High Priestess dormer 10-20% fetal calf serum-containing RPMI-1640 medium, cultured in an animal cell culture medium such as MEM medium, normal culture conditions (e.g.
- a monoclonal antibody By culturing for 3 to 10 days, a monoclonal antibody can be obtained from the culture supernatant.
- the hybridoma can be transplanted into the abdominal cavity of a mouse or the like, and ascites can be collected 10 to 14 days later, and a monoclonal antibody can be obtained from the ascites.
- a human antibody or a humanized antibody for use in administering monoclonal antibodies to humans (antibody therapy)
- the human antibody or humanized antibody is prepared by, for example, preparing a hybridoma using a mouse or the like into which a human antibody gene has been introduced as an immunized animal, or using a library displaying the antibody on phage. Can be obtained.
- a transgenic animal having a repertoire of human antibody genes is immunized with a protein serving as an antigen, a protein-expressing cell or a lysate thereof to obtain antibody-producing cells, which are then used as myeloma cells.
- a human antibody against the target protein can be obtained (see International Publication Nos. W092-03918, W093-2227, W094-02602, W096-33735 and W096-34096). Further, by selecting a phage displaying an antibody that binds to a protein serving as an antigen, a protein-expressing cell or a lysate thereof from an antibody library in which a plurality of different human scFvs are displayed on the phage, One can select sc Fvs that bind to proteins (Griffiths. Et al., EMBO J. 12, 725-734, 1993).
- the diagnostic method of the present invention provides a method for measuring the level of expression of a gene encoding protein (a) or (b) in a specimen collected from a test animal, whereby the test animal suffers from a disease associated with enhanced expression of the gene. It includes the step of diagnosing whether or not it is performing. Since the gene encoding the protein (a) or (b) is not upregulated in normal cells or tissues but is upregulated only in abnormal cells or tissues, the expression level of the gene is determined by the expression level of the gene. It can be used as an index for diagnosis of a disease associated with hypertension.
- test animals are not particularly limited, and include, for example, mammals such as humans, monkeys, sea lions, sheep, sheep, goats, horses, pigs, rabbits, dogs, cats, rats, and mice.
- the sample collected from the test animal is not particularly limited.
- blood, serum, and the like can be used in addition to cells of the tissue or organ to be diagnosed.
- the tissue or organ to be diagnosed is not particularly limited.
- brain without, for example, brain, pituitary, spinal cord, salivary gland, thymus, thyroid, lung, breast, skin, skeletal muscle, heart, liver, spleen, adrenal gland, knee, stomach, small intestine, large intestine, rectum, bladder, prostate, Testis, ovary, placenta, uterus, bone marrow, peripheral mononuclear cells and the like.
- the “expression level of the gene encoding the protein (a) or (b)” includes the transcription level of the gene encoding the protein (a) or (b) to mRNA and the level of transcription of the gene encoding the protein (a) or (b). Translation level is included. Therefore, the expression level of the gene encoding the protein (a) or (b) in the specimen is determined by the abundance of the mRNA encoding the protein (a) or (b) in the specimen or the protein (a) in the specimen. Alternatively, it can be measured based on the abundance of (b).
- a known gene analysis technique for example, a hybridization technique (for example, Northern hybridization, dot blot, DNA Microarray method), gene amplification technology (eg, RT-PCR, etc.) can be used.
- a hybridization technique for example, Northern hybridization, dot blot, DNA Microarray method
- gene amplification technology eg, RT-PCR, etc.
- oligonucleotide or polynucleotide probe capable of hybridizing to the nucleic acid encoding the protein (a) or (b).
- the oligonucleotide or polynucleotide can be used as a primer.
- the “nucleic acid encoding the protein (a) or (b)” includes both DNA and RNA, and includes, for example, mRNA, cDNA, cRNA and the like.
- the nucleotide constituting the oligonucleotide or the polynucleotide may be any of a deoxyliponucleotide and a ribonucleotide.
- the base length of the oligonucleotide is not particularly limited, but is usually 1 It is 5 to 100 bases, preferably 18 to 30 bases.
- the base length of the polynucleotide is not particularly limited, but is usually 50 to 100 bases, and preferably 200 to 800 bases.
- nucleic acid encoding (b).
- “Specifically hybridizable” means that it can hybridize under stringent conditions, and “stringent conditions” include, for example, 42 ° C, 2 XSSC and 0.1%. SDS conditions, preferably at 65 ° C, 0.133 ⁇ and 0.1% SDS.
- stringent conditions include, for example, 42 ° C, 2 XSSC and 0.1%. SDS conditions, preferably at 65 ° C, 0.133 ⁇ and 0.1% SDS.
- Oligonucleotides or polynucleotides are, for example, proteins (a).
- the synthesized cDNA was converted into type II, and the cDNA encoding the protein (a) or (b) was converted to cDNA.
- the abundance of mRNA encoding the protein (a) or (b) can be measured.
- the PCR is performed under conditions (for example, the number of PCR cycles at which the PCR amplified fragment increases exponentially) so that the amount of PCR amplified fragment production reflects the amount of the initial type III cDNA.
- the method for quantifying the PCR amplified fragment is not particularly limited, and the PCR amplified fragment can be quantified by, for example, a quantification method using a radioisotope (RI), a quantification method using a fluorescent dye, or the like.
- RI radioisotope
- Examples of the quantification method using RI include: (i) adding a RI-labeled nucleotide (for example, 32 P-labeled dCTP, etc.) as a substrate to a reaction solution, incorporating the nucleotide into a PCR-amplified fragment, and collecting the PCR-amplified fragment. RI labeling, separation of PCR amplified fragments by electrophoresis, etc., followed by measurement of radioactivity to quantify PCR amplified fragments. (Ii) By using RI-labeled primers?
- a RI-labeled nucleotide for example, 32 P-labeled dCTP, etc.
- a method of quantifying a PCR-amplified fragment by measuring the radioactivity by blotting, hybridizing a probe labeled with RI, and the like can be mentioned.
- the radioactivity can be measured using, for example, a liquid scintillation counter, an X-ray film, an imaging plate, or the like.
- Quantitative methods using fluorescent dyes include: (i) staining of PCR-amplified fragments using a fluorescent dye that interacts with double-stranded DNA (for example, ethidium amide (EtBr), SYBR GreenI, PicoGreen, etc.) Quantifying the PCR-amplified fragment by measuring the intensity of the fluorescence emitted by the excitation light irradiation, and (ii) labeling the PCR-amplified fragment with a fluorescent dye by using a primer labeled with a fluorescent dye. After the fragments are separated by electrophoresis or the like, a method of measuring the fluorescence intensity and quantifying the PCR-amplified fragments can be used. Fluorescent intensity The degree can be measured using, for example, a CCD camera, a fluorescence scanner, a spectrofluorometer, or the like.
- a known protein analysis technique for example, a Western plotting method using an antibody or a fragment thereof capable of reacting with the protein (a) or (b), Immunoprecipitation, ELISA, tissue immunostaining, etc. can be used.
- a protein (a) or (b) in a sample is captured using a solid-phase carrier (eg, immunoplate, latex particles, etc.) to which antibodies are bound by physical adsorption, chemical bonding, or the like. After that, the captured protein (a) or
- (b) is different from an antibody immobilized on a solid phase carrier in a labeled antibody (for example, an enzyme such as peroxidase or alkaline phosphatase, a fluorescent substance such as floretensens or pumbelliferone) in which the antigen recognition site for protein (a) or (b) is different. , Etc.).
- a labeled antibody for example, an enzyme such as peroxidase or alkaline phosphatase, a fluorescent substance such as floretensens or pumbelliferone
- the measurement of the abundance of the protein (a) or (b) in the sample can also be performed by measuring the activity of the protein (a) or (b) in the sample.
- the activity of the protein (a) or (b) can be measured, for example, by a known method such as a western blotting method and an ELISA method using an antibody or a fragment thereof capable of reacting with the protein (a) or (b).
- the measured value of the expression level of the gene encoding the protein ( a ) or (b) is based on the measured value of the expression level of the gene encoding the protein whose expression level does not fluctuate significantly (for example, -actin, GAPDH). It is preferable to correct.
- protein in a specimen taken from a subject animal (a) or expression level of the gene encoding the (b) is a protein in a specimen taken from a healthy animal (a) or (b)
- the test animal can be diagnosed as suffering from a disease associated with the increased expression of the gene.
- the same type of cell or tissue (including organs) is used as the specimen.
- the protein (a) or the protein (a) in a plurality of healthy animals (healthy animal group) is compared. Quantifying the expression level of the gene encoding (b) and setting a normal range based on the distribution of the values, the expression level of the gene encoding the protein (a) or (b) in the test animal becomes higher than the normal range It is preferable to determine whether the temperature falls below the normal range. At this time, when the expression level of the gene in the specimen of the test animal is higher than the normal range, it can be diagnosed that the test animal has the disease.
- the diagnostic method of the present invention can be widely used for diseases associated with enhanced expression of the gene encoding the protein (a) or (b), and the types of diseases that can be diagnosed are not particularly limited.
- “enhancement of gene expression is involved” includes both cases in which a gene develops as a result of a disease and a disease develops, and cases in which a disease develops as a result of an increase in gene expression.
- Diseases that can be diagnosed by the diagnostic method of the present invention include, for example, lung cancer, and examples of lung cancer include lung adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and small cell lung cancer.
- the diagnostic method of the present invention is useful for diagnosis of lung adenocarcinoma among these lung cancers.
- metastatic from colorectal cancer, gastric cancer, etc. From the fact that the gene expression profiles of lung cancer tissue and primary lung cancer tissue tend to be different (Arindam Bhattacharjee et al., PNAS, Vol. 98, 13790-13795, 2001), the diagnostic method of the present invention provides a method for diagnosing primary lung cancer. Particularly useful for diagnosis.
- lung cancer When diagnosing lung cancer, lung cells, lung tissue, blood, serum, etc., collected from a test animal are usually used as the specimen, but the protein (a) or ( Since the expression of the gene encoding b) may be increased in some cases, lung cancer can be diagnosed by using tissues and organs other than the lung. However, if tissues or organs other than the lungs are used, the expression of the gene encoding the protein (a) or (b) may be enhanced S, or may be due to a unique abnormality in the tissues or organs other than the lungs or lung cancer cells. Because it is indistinguishable from metastasis, it is only possible to diagnose whether or not the disease that may have affected the test animal includes lung cancer.
- the diagnostic kit of the present invention comprises an oligonucleotide or polynucleotide capable of hybridizing to a nucleic acid encoding the protein (a) or (b), or an antibody or a fragment thereof capable of reacting with the protein (a) or (b). Including. These oligonucleotides, polynucleotides, antibodies or fragments thereof can be used as reagents for measuring the expression level of the gene encoding the protein (a) or (b) in a specimen collected from a test animal. It is possible to diagnose whether a test animal is suffering from a disease associated with enhanced expression of the gene by using the diagnostic kit of the present invention included in the kit for use in the present invention.
- the diagnostic kit of the present invention may be in any form as long as it contains the above-mentioned oligonucleotide or polynucleotide, or the above-mentioned antibody or fragment thereof, and may contain any reagents, instruments and the like.
- the diagnostic kit of the present invention contains the above-mentioned oligonucleotide or polynucleotide, the reagents necessary for PCR (for example, H 2 O, buffer, M g C 1 2 S d NTP Mix, T aq polymerase, etc.), quantitation necessary reagents PCR amplification fragments (e.g. RI, fluorescent dyes, etc.), DNA microarray I, one such as a DNA chip or 2 More than one type can be included.
- the reagents necessary for PCR for example, H 2 O, buffer, M g C 1 2 S d NTP Mix, T aq polymerase, etc.
- quantitation necessary reagents PCR amplification fragments e.g. RI, fluorescent dyes, etc.
- DNA microarray I one such as a DNA chip or 2 More than one type can be included.
- a solid phase carrier eg, immunoplate, latex particles, etc.
- a solid phase carrier for immobilizing the antibody or the fragment thereof
- glodalin antibodies secondary antibodies
- antibodies including secondary antibodies
- fragments thereof eg, enzymes, fluorescent substances, etc.
- various reagents eg, enzyme substrates, buffers, diluents, etc.
- One or more types can be included.
- the screening method of the present invention provides a method for screening a gene encoding a protein (a) or (b) in a cell or tissue (including an organ) in which the expression level of a gene encoding the protein (a) or (b) is enhanced.
- the method includes a step of determining the preventive and therapeutic effects of a candidate substance on a disease associated with enhanced expression of the gene using the effect of reducing the expression level as an index.
- prevention or treatment of a disease associated with enhanced expression of the gene is selected.
- the material can be screened.
- the screening method of the present invention can be widely used for the prevention and treatment of a disease associated with enhanced expression of a gene encoding a protein (a) or (b), and for the screening of a therapeutic substance. Is not particularly limited.
- Diseases to be targeted by the screening method of the present invention include, for example, lung cancer.
- lung cancer include lung adenocarcinoma, lung squamous cell carcinoma, large cell lung cancer, and small cell lung cancer.
- the screening method of the present invention is useful for screening a substance having a preventive / therapeutic effect particularly on lung adenocarcinoma among these lung cancers.
- the "protein ( a ) or (b) The effect of reducing the expression level of the gene encoding the protein includes any effect on any step such as transcription / translation of the gene encoding the protein (a) or (b), and expression of the activity of the protein (a) or (b). included.
- the screening method of the present invention can be performed both in vivo and in vitro.
- a specimen before administration of the candidate substance
- Cells or tissues with an elevated expression level of the gene are collected, the expression level of the gene in the sample is measured, and the gene after administration of the candidate substance is measured.
- the preventive / therapeutic effect of a candidate substance for a disease associated with enhanced expression of the gene is determined using the effect of reducing the expression level of the gene as an index, and the preventive / therapeutic substance for the disease can be screened based on this result.
- Model animals used in the in vivo screening method include, for example, mammals such as humans, magpies, higgins, goats, magpies, pigs, magpies, dogs, cats, rats, mice, etc. Is mentioned.
- a transjugated animal in which the expression level of the gene encoding the protein (a) or (b) is artificially enhanced can also be used as a model animal to which the catching substance is administered.
- Such transgenic animals can be produced, for example, by (i) a method of mixing a gene encoding a protein (a) or (b) with an egg and treating the mixture with calcium phosphate, (ii) a method using a phase contrast microscope.
- Known methods such as a method for directly introducing a gene encoding a protein (a) or (b) into the nucleus of pronuclear stage eggs (microinjection method), and a method using (iii) embryonic stem cells (ES cells) Can be obtained by To increase the expression level of the gene encoding the protein (a) or (b) in the transgenic animal, the gene must be introduced as a foreign gene and forcedly expressed. It includes any of the following states: a state in which the expression level of the gene inherently possessed by the host is elevated; and a state in which the degradation of the protein (a) or (b) is suppressed.
- cells used in the in vitro screening method for example, cell lines derived from human, monkey, mouse, rat and the like can be used.
- cells in which the expression level of the gene encoding the protein (a) or (b) is artificially enhanced can also be used.
- Such cells can be obtained by inserting a gene encoding the protein (a) or (b) into an appropriate expression vector and introducing the vector into an appropriate host cell.
- the screening kit of the present invention comprises an oligonucleotide or polynucleotide capable of hybridizing to a nucleic acid encoding the protein (a) or (b), an antibody capable of reacting with the protein (a) or (b), or an antibody or Including its fragments.
- These oligonucleotides, polynucleotides, antibodies or fragments thereof are used as reagents for measuring the expression level of the gene encoding protein ( a ) or (b) in a specimen collected from a test animal.
- the screening kit of the present invention may be in any form as long as it contains the above-mentioned oligonucleotide or polynucleotide, or the above-mentioned antibody or fragment thereof, and various reagents, instruments, etc. exemplified in the above-mentioned diagnostic kit.
- it can include candidate substances, candidate substance synthesis kits, model animal breeding kits, and the like.
- the present invention will be specifically described with reference to the following examples, but the present invention is not limited thereto.
- Gene manipulation using Escherichia coli or the like was basically performed according to the method described in Molecular Claw; Long (Cold spring harbor lab. Press 1989).
- Example 1 Identification of genes specifically expressed in human lung adenocarcinoma tissues
- mRNA expression analysis in human lung adenocarcinoma excised tissues was performed.
- RNA g prepared from one normal lung was used as a sample.
- Gene expression analysis was performed according to Manual (Affytnetryx). The average value of the expression scores of all genes in each analysis was set to 100, and the expression level of each gene was determined as a relative value.
- H T Used various organs shown in Table 1. Gene expression analysis was performed in the same manner as described above, using each lOng of human organ-derived RNA as a sample. The average value of the expression scores of all genes was set to 100, and the relative value was calculated.
- the target sequence of U133B is human EST (GenBank Accession No. AA213814), but this human EST (GenBank Accession No. AA213814) has an unidentified base sequence.
- G PCR primers used for cDNA isolation GSP1 (SEQ ID NO: 3), GSP2 (SEQ ID NO: 4) and GSP3 (SEQ ID NO: 5) based on the X chromosome sequence information including EST (GenBank Accession No. AA213814) Were designed, and cDNAs on the 5, 5 and 3 ′ sides of the probe target sequence were amplified using SMART TM RACE cDNA Amplification kit (Clontech).
- Single-stranded cDNA was synthesized according to the method attached to the kit based on about 400 ng obtained by mixing three RNAs of the total RNA prepared from the lung adenocarcinoma tissue, followed by PCR primer GSP1 (SEQ ID NO: 3). And 5SP cDNA using GSP2 (SEQ ID NO: 4). That is, a PCR reaction was performed according to the method attached to the kit, using 1.L single-stranded cDNA as type I DNA and 5 pmole of GSP1 (SEQ ID NO: 3) or GSP2 (SEQ ID NO: 4) as a PCR primer.
- the PCR was performed for 5 cycles of a first 5 seconds at 94 ° C, followed by 3 minutes at 72 ° C, followed by 5 seconds at 94 ° C, 10 seconds at 70 ° C, and A 3-minute cycle at 72 ° C
- the reaction was performed for 5 cycles, and finally the reaction was performed at 94 ° C for 5 seconds, 68 ° C for 10 seconds, and 72 ° C for 3 minutes for 25 cycles.
- FIG. 3 shows the results of electrophoresis of the PCR product (1% agarose electrophoresis followed by ethidium / membranide staining).
- M indicates a molecular weight marker (lkbp plus DNA Ladder (Invitrogen)).
- the amplification product obtained by this PCR reaction is introduced into a pGEM-Teasy vector (Promega), and E. coli DH5a (Toyobo) is transformed by a conventional method. Then, plasmid MA is prepared from the resulting transformant. did.
- nucleotide sequence of the inserted gene of plasmid DNA of about 2000 bp was analyzed.As a result, a gene sequence having several different bases was obtained.
- the consensus clone was named gene # 15, and its full-length nucleotide sequence was It is shown in SEQ ID NO: 1.
- Gene nucleotide sequence that would open reading frame of # 15 is from 103 to 1488 th of the base sequence of SEQ ID NO: 1, and c shows the amino acid sequence encoded by this open Li one reading frame in SEQ ID NO: 2
- Table 2 shows a list of the mutation sites of each clone, which were found by comparing each clone with several bases different from gene # 15.
- the amplified product of about 2500 bp contained a nucleotide sequence in which the 5 ′ UTR was further extended upstream from gene # 15, and did not contain a coding region.
- the nucleotide sequence of the 5 ′ UTR region is shown in SEQ ID NO: 13.
- the base sequence up to position 472 is the base sequence of the 5 ′ UTR
- the base sequence 473 and following is the base sequence of the coding region (the base sequence of the coding region of gene # 15). The same base sequence).
- base position is the number when A in the start code of gene # 15 (SEQ ID NO: 1) is the first.
- the amino acids underlined do not change in type due to changes in the base sequence.
- the 3 ′ cDNA was isolated using the SMART TM RACE cDNA Amplification kit (Clontecli) as described above. That is, single-stranded cDNA was synthesized according to the method attached to the kit, based on one mixture of total RNAs prepared from three tissues derived from lung adenocarcinoma patients, according to the method attached to the kit. Subsequently, cDNA amplification was performed using 1.2 ⁇ ⁇ L of the single-stranded cDNA as ⁇ -type DNA and 5 pmole of GSP3 (SEQ ID NO: 5;;) as a PCR primer. In addition, PCR performed the same reaction as above.
- LOC139320 (GenBank Accession No. XM_066619) was found. Alignment results between the nucleotide sequence of gene # 15 and the nucleotide sequence of L0C139320 are shown in FIGS. As shown in Figs. 4 and 5, the nucleotide sequence was completely identical between the isolated gene # 15 and L0C139320, but the sequence of the 5 'region and the sequence of the intermediate region were different.
- I was L0C139320 is a nucleotide sequence predicted from the human genome sequence, although it is present in the X chromosome (Xq22.1) similar to the target sequence of 230349-at_ul33B and has a partial nucleotide sequence completely identical.
- a PCR primer for the 5 'transcription initiation region of gene # 15 SEQ ID NO: 6
- a PCR primer for the 5' transcription initiation region of L0C139320 SEQ ID NO: 7
- a common PCR primer for the 3 'region SEQ ID NO: 7
- mRNA derived from gene # 15 was confirmed by RT-PCR and expression analysis using GeneChip (Gene Chip TM HG-133B Target; Af fymetryx).
- Gene # 15 expression was compared in lung adenocarcinoma tissue (12 cases) and normal lung tissue (4 cases).
- the nucleotide sequence at positions 1214 to 1238 of SEQ ID NO: 1 is used as a PCR primer # 15—RF (SEQ ID NO: 9) in the sense direction, and the nucleotide sequence at positions 1402 to 1378 in SEQ ID NO: 1 is used as a PCR primer # 15_RR ( SEQ ID NO: 10).
- PCR primer # 15—RF SEQ ID NO: 9
- PCR primer # 15_RR SEQ ID NO: 10
- a single-stranded cDNA synthesized from total RNA using reverse transcriptase Superscriptll (GIBCO BRL) was subjected to a PCR reaction as type I DNA, and the
- PCR reaction solution in each 25 mu L is, 500raM KC1, 100 mM Tri s -HCl (pH8. 3), 20mM MgCl 2, 0. 1% Gelatin, each 1. 25mM dNTPs (dATP, dCTP, dGTP, dTTP), 1 ⁇ L of single-stranded C DNA, 5 pmole each of sense primer # 15_RF (SEQ ID NO: 9), antisense primer # 15-RR (Rooster column number 10), 0.25 ⁇ L of recombinant t Taq polymerase Mix (FG Pluthero, Rapid purification of high-activity Taq DNA polymerase, Nucl. Acids. Res.
- RNA gene # 1 5 while it is increased expression with high frequency in lung adenocarcinoma tissue was observed, even Ya infiltrating lymphocytes in addition adenocarcinoma cells in cancer tissues such as lung cancer It is known that tissues such as connective tissues are also mixed, and it is necessary to clarify in which cells the expression of gene # 15 is enhanced.
- a Multi-Tissue Tissue cDNA Panel Human containing cDNA prepared from various inactive and activated immune cells was used.
- PCR was performed in the same manner as described above.
- lymphocytes of which 80% are T lymphocytes and the rest are B lymphocytes.
- the remaining about 1/3 is considered to be infiltrated macrophages, and it is reported that NK cells and dendritic cells are slightly present (Agapi Kataki et al., J Lab Clin Med, Vol 140, 320-3 28, 2002).
- gene # 15 may be specifically up-regulated in lung adenocarcinoma cells of lung adenocarcinoma tissues.
- gene # 15 in normal human tissues was analyzed by quantitative PCR as described above. At this time, Multiple Tissue cDNA Panels Human I and II (manufactured by Clontech) were used as single-stranded cDNA prepared from normal human tissues. The single-stranded cDNA for 5 'RACE prepared above was used as a positive control.
- RNA was prepared in the same manner as above, and after mixing equal amounts, Similarly, gene # 1 ⁇ expression was analyzed using GeneChip TM HG-U133B (Affymetryx).
- a novel protein that is specifically upregulated in abnormal cells or tissues particularly lung cancer cells or tissues
- a gene encoding the protein a recombinant vector containing the gene
- a transformation containing the recombinant vector Also provided are antibodies against the above proteins.
- the expression of a gene encoding a protein that specifically enhances the expression in abnormal cells or tissues is used as an index, and the expression of the gene is involved in the enhancement.
- a diagnostic method and a diagnostic kit for a disease are provided.
- the expression of a gene encoding a protein that is specifically upregulated in abnormal cells or tissues is involved in the enhancement of the expression of the gene as an index.
- a method for screening for the prevention and treatment of diseases and a kit for screening are provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003292721A AU2003292721A1 (en) | 2002-12-27 | 2003-12-26 | Novel protein and its gene |
JP2004564565A JPWO2004061103A1 (ja) | 2002-12-27 | 2003-12-26 | 新規タンパク質及びそれをコードする遺伝子 |
EP03768371A EP1589101A4 (en) | 2002-12-27 | 2003-12-26 | NEW PROTEIN AND ITS GENE |
US11/166,336 US20060135750A1 (en) | 2002-12-27 | 2005-06-24 | Novel protein and gene encoding the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002382418 | 2002-12-27 | ||
JP2002-382418 | 2002-12-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/166,336 Continuation US20060135750A1 (en) | 2002-12-27 | 2005-06-24 | Novel protein and gene encoding the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004061103A1 true WO2004061103A1 (ja) | 2004-07-22 |
Family
ID=32708596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/017064 WO2004061103A1 (ja) | 2002-12-27 | 2003-12-26 | 新規タンパク質及びそれをコードする遺伝子 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060135750A1 (ja) |
EP (1) | EP1589101A4 (ja) |
JP (1) | JPWO2004061103A1 (ja) |
AU (1) | AU2003292721A1 (ja) |
WO (1) | WO2004061103A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130189268A1 (en) * | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
CN109781998B (zh) * | 2019-02-20 | 2022-03-25 | 首都医科大学附属北京中医医院 | Hmgb1基因或蛋白表达在评估芪归银治疗肺炎效果中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072831A2 (en) * | 2001-01-25 | 2002-09-19 | Pe Corporation (Ny) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1368475A4 (en) * | 2001-03-15 | 2004-10-20 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
-
2003
- 2003-12-26 JP JP2004564565A patent/JPWO2004061103A1/ja active Pending
- 2003-12-26 WO PCT/JP2003/017064 patent/WO2004061103A1/ja not_active Application Discontinuation
- 2003-12-26 EP EP03768371A patent/EP1589101A4/en not_active Withdrawn
- 2003-12-26 AU AU2003292721A patent/AU2003292721A1/en not_active Abandoned
-
2005
- 2005-06-24 US US11/166,336 patent/US20060135750A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072831A2 (en) * | 2001-01-25 | 2002-09-19 | Pe Corporation (Ny) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
Non-Patent Citations (2)
Title |
---|
HO M. ET AL.: "Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein", CELL, vol. 77, 17 June 1994 (1994-06-17), pages 869 - 880, XP002977889 * |
See also references of EP1589101A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1589101A1 (en) | 2005-10-26 |
EP1589101A4 (en) | 2006-01-18 |
US20060135750A1 (en) | 2006-06-22 |
JPWO2004061103A1 (ja) | 2006-05-11 |
AU2003292721A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7812128B2 (en) | Gene overexpressed in cancer | |
EP2311468B1 (en) | Gene overexpressed in cancer | |
JP2004113151A (ja) | 癌遺伝子及びその用途 | |
JP2004198419A (ja) | Timp1を用いた検出方法 | |
WO2001009318A1 (fr) | Genes associes au cancer du foie | |
MX2011001445A (es) | Metodo para detectar cancer. | |
WO1998018945A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
EP0973944A1 (en) | Reagents and methods useful for detecting diseases of the gastrointestinal tract | |
WO2001025427A1 (fr) | Adn reagissant a la contrainte de cisaillement | |
US8722350B2 (en) | Methods and compositions for categorizing patients | |
EP1576109A2 (en) | Methods and compositions for categorizing patients | |
US7666603B2 (en) | Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene | |
WO2004061103A1 (ja) | 新規タンパク質及びそれをコードする遺伝子 | |
JP2004159600A (ja) | 癌の診断方法及び癌の診断用キット | |
EP1246914A2 (en) | Nope polypeptides, encoding nucleic acids and methods of use | |
JP2006512923A (ja) | 癌関連遺伝子ファミリー | |
JP4912657B2 (ja) | 大腸癌マーカー遺伝子 | |
KR20070027659A (ko) | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 | |
CA2491420A1 (en) | Rb1 gene induced protein (rb1cc1) and gene | |
JP4301541B2 (ja) | Smg−1結合タンパク質及びその活性を制御する物質のスクリーニング方法 | |
WO2000004142A1 (en) | Mucins | |
JP2003230388A (ja) | 糖・脂質代謝異常疾患マーカーおよびその利用 | |
JPWO2005080562A1 (ja) | 前立腺癌の判定方法 | |
JP2004242644A (ja) | グアノシン三リン酸結合タンパク質共役型の受容体 | |
AU4888799A (en) | Mucins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11166336 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004564565 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003768371 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003768371 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11166336 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003768371 Country of ref document: EP |